search
Back to results

Cotrimoxazole Versus Amoxicillin in the Treatment of Community Acquired Pneumonia in Children Aged 2-59 Months

Primary Purpose

Childhood Pneumonia

Status
Completed
Phase
Phase 3
Locations
Uganda
Study Type
Interventional
Intervention
Amoxicillin
Cotrimoxazole
Amoxicillin placebo
Cotrimoxazole placebo
Sponsored by
Makerere University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Childhood Pneumonia focused on measuring Efficacy, children, pneumonia, cotrimoxazole, amoxicillin

Eligibility Criteria

2 Months - 59 Months (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Children aged 2-59 months with non severe pneumonia based on WHO criteria of respiratory rate above the age specific cut-off
  • Accessible to follow up
  • Written informed consent from the parent/caretaker

Exclusion Criteria:

  • Children with severe pneumonia
  • Documented use of antibiotics for the last 48 hours
  • Confirmed HIV positive on cotrimoxazole prophylaxis
  • Three or more episodes of wheezing in a year with asthmatic attack
  • History of hospitalization within last 15 days
  • Measles within last one month
  • Previous history of allergy to cotrimoxazole or amoxicillin

Sites / Locations

  • Faculty of Medicine, Makerere University

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Cotrimoxazole

Amoxicillin

Arm Description

Cotrimoxazole (8 mg/kg/dose trimethoprim + 40 mg/kg/dose sulphamethoxazole) + Amoxicillin placebo

Amoxicillin (25 mg/kg/dose) + Cotrimoxazole placebo

Outcomes

Primary Outcome Measures

Normalisation of respiratory rate to age specific range by day 3 of treatment

Secondary Outcome Measures

Antimicrobial susceptibility to cotrimoxazole and amoxicillin

Full Information

First Posted
July 5, 2009
Last Updated
July 6, 2009
Sponsor
Makerere University
search

1. Study Identification

Unique Protocol Identification Number
NCT00933049
Brief Title
Cotrimoxazole Versus Amoxicillin in the Treatment of Community Acquired Pneumonia in Children Aged 2-59 Months
Official Title
Clinical Efficacy of Cotrimoxazole Versus Amoxicillin in the Treatment of Community Acquired Pneumonia in Children Aged 2-59 Months Attending Mulago Hospital: A Randomized Clinical Trial.
Study Type
Interventional

2. Study Status

Record Verification Date
July 2009
Overall Recruitment Status
Completed
Study Start Date
July 2007 (undefined)
Primary Completion Date
January 2008 (Actual)
Study Completion Date
January 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Makerere University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The investigators hypothesized that Oral amoxicillin (25mg/kg/dose bid) given to children aged 2-59 months with pneumonia, would lead to better clinical outcome on day three in 89.9% of the children compared to 77.0% of children receiving oral cotrimoxazole (8 mg/kg/dose trimethoprim, 40 mg/kg/dose sulphamethoxazole). A double blind randomized controlled trial was conducted in the Assessment Center of Mulago Hospital. Children with non-severe pneumonia were randomized to receive either oral amoxicillin (25 mg/kg/dose) or cotrimoxazole (trimethoprim 8 mg/kg and sulphamethoxazole 40 mg/kg) and followed up on day 3 and 5 of treatment. The primary outcome measures were normalization of respiratory rate by day 3 of treatment. Secondary outcome measures were antimicrobial susceptibility to cotrimoxazole and amoxicillin.
Detailed Description
A triage Nurse identified and recorded children aged 2- 59 months who presented with a history of cough, difficult breathing, or fast breathing (tachypnea) in the Assessment Center of Mulago Hospital. Children aged 2-11 months with a respiratory rate>50 breaths per minute and those aged 12-59 months with a respiratory rate of > 40 breaths per minute were enrolled into the study following informed consent from parents/caretakers. Clinical history included the patient's detailed record of the illness, previous medical history and antibiotic use in the current illness. The IMCI approach was particularly employed during history taking and examination. The Principle Investigator and the research assistant interviewed the caretakers using a structured questionnaire. 5 mls of blood was drawn from the ante cubital fossa for a complete blood count and blood cultures.In addition thin and thick blood smears for malaria parasites were taken using finger prick blood samples. Rapid HIV antibody test was done to determine the HIV serostatus of the children. Children less than 18 months with a positive antibody test were referred to the Paediatric Infectious Disease Clinic (PIDC) Mulago Hospital for a DNA-PCR test to confirm their HIV infection status. Study participants were placed in a well aerated room and subjected to sputum induction. The principal investigator, with the help of the research assistant and a nurse performed the procedure. The study patients were nebulised with salbutamol at a dose of 0.1mg/kg in 3ml of Normal saline. 3mls of 3% sterile saline was administered through a facemask nebuliser for about 10-15 minutes.Sputum was obtained by expectoration (in children who could do it) or by nasopharyngeal suction in those who were unable to expectorate. Gram stain, ZN stain and culture and sensitivity was performed on sputum. Oxygen saturation was measured before and after sputum induction. For those children who had oxygen saturation of less than 92% or could not tolerate the sputum induction, the procedure was deferred to the following day when the children were more stable. However, they continued with treatment. Treatment assignment was concealed from patients, parents, and study personnel. Children assigned co-trimoxazole received active medicine (8 mg/kg/dose trimethoprim + 40 mg/kg/dose sulphamethoxazole) and amoxicillin placebo twice a day. Children assigned amoxicillin received active medicine (25 mg/kg/dose) and co-trimoxazole placebo twice a day.A randomization scheme was developed using a table of random numbers generated by computer. Study participants were randomly assigned to treatment in blocks of 4 to 12. Both drugs and placebo were manufactured and packaged in volumes of 100mls and had the same color. Treatment was started as soon as patients were enrolled in the study after withdrawal of blood and sputum samples. Drug doses were calculated according to the body weight. Cotrimoxazole was given orally (syrup) in a dose of 8mg/kg/dose trimethoprim, 40mg/kg/dose sulphamethoxazole and oral (syrup) amoxicillin in a dose of 25mg/kg/dose every 12 hours until a total of 5 days was reached. The study had two treatment arms; one arm was randomly assigned to receive active amoxicillin plus placebo cotrimoxazole orally and the other arm was randomly assigned to receive active cotrimoxazole with placebo amoxicillin two doses per day. The study nurse and the principle investigator demonstrated to the parent/caretaker how to give the study drugs by giving the first dose from the clinic. An explanation was given on how to give medication at home and the level of understanding was checked before leaving clinic. Caretakers were instructed not to give any other medications especially antibiotics other than those given in the hospital and were instructed to return to the clinic on day 3 and 5 of treatment. Paracetamol syrup was administered to febrile children at a dose of 15 mg/kg 4 - 6 hourly if their axillary temperature were 38.5 degrees Celsius and above. Vitamin A was given according to the national recommendation guidelines. Patients who were diagnosed with malaria from blood slides were given Arthemeter-Lumefantrine tablets. Other medications were as well given according to the presentation and the diagnosis.The day of enrollment was counted as day 0. After three days of treatment, patients were checked for general danger signs and assessed for cough or difficult breathing and the respiratory rate counted. Improvement was defined as slower respiratory rate (either back to normal range for age, or more than 5 breaths per minute lower compared to the previous evaluation), less fever, normal oxygen saturation and better appetite, then patients were requested to complete the 5 days antibiotics and final follow up on the day 5 of treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Childhood Pneumonia
Keywords
Efficacy, children, pneumonia, cotrimoxazole, amoxicillin

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
505 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cotrimoxazole
Arm Type
Active Comparator
Arm Description
Cotrimoxazole (8 mg/kg/dose trimethoprim + 40 mg/kg/dose sulphamethoxazole) + Amoxicillin placebo
Arm Title
Amoxicillin
Arm Type
Active Comparator
Arm Description
Amoxicillin (25 mg/kg/dose) + Cotrimoxazole placebo
Intervention Type
Drug
Intervention Name(s)
Amoxicillin
Other Intervention Name(s)
AMOX
Intervention Description
Oral amoxicillin (25mg/kg/dose)for 5 days
Intervention Type
Drug
Intervention Name(s)
Cotrimoxazole
Other Intervention Name(s)
CTX
Intervention Description
Cotrimoxazole (8 mg/kg/dose trimethoprim + 40 mg/kg/dose sulphamethoxazole)
Intervention Type
Drug
Intervention Name(s)
Amoxicillin placebo
Intervention Type
Drug
Intervention Name(s)
Cotrimoxazole placebo
Primary Outcome Measure Information:
Title
Normalisation of respiratory rate to age specific range by day 3 of treatment
Time Frame
3 days
Secondary Outcome Measure Information:
Title
Antimicrobial susceptibility to cotrimoxazole and amoxicillin
Time Frame
10 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Months
Maximum Age & Unit of Time
59 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Children aged 2-59 months with non severe pneumonia based on WHO criteria of respiratory rate above the age specific cut-off Accessible to follow up Written informed consent from the parent/caretaker Exclusion Criteria: Children with severe pneumonia Documented use of antibiotics for the last 48 hours Confirmed HIV positive on cotrimoxazole prophylaxis Three or more episodes of wheezing in a year with asthmatic attack History of hospitalization within last 15 days Measles within last one month Previous history of allergy to cotrimoxazole or amoxicillin
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joyce M Kaducu, MBChB, MMED
Organizational Affiliation
Makerere University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Faculty of Medicine, Makerere University
City
Kampala
Country
Uganda

12. IPD Sharing Statement

Learn more about this trial

Cotrimoxazole Versus Amoxicillin in the Treatment of Community Acquired Pneumonia in Children Aged 2-59 Months

We'll reach out to this number within 24 hrs